Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group.
Nielsen LK, Schjesvold F, Möller S, Guldbrandsen N, Hansson M, Remes K, Peceliunas V, Abildgaard N, Gregersen H, King MT. Nielsen LK, et al. Among authors: schjesvold f. J Patient Rep Outcomes. 2024 Feb 5;8(1):15. doi: 10.1186/s41687-024-00691-2. J Patient Rep Outcomes. 2024. PMID: 38315268 Free PMC article. Clinical Trial.
[Investigation of amyloidosis].
Schjesvold FH. Schjesvold FH. Tidsskr Nor Laegeforen. 2013 Feb 5;133(3):266. doi: 10.4045/tidsskr.13.0044. Tidsskr Nor Laegeforen. 2013. PMID: 23381155 Free article. Norwegian. No abstract available.
[Monoclonal gammopathy of clinical importance].
Tjønnfjord GE, Schjesvold FH, Gulbrandsen N, Kvam AK. Tjønnfjord GE, et al. Tidsskr Nor Laegeforen. 2021 Sep 24;141(2021-13). doi: 10.4045/tidsskr.20.0981. Print 2021 Sep 28. Tidsskr Nor Laegeforen. 2021. PMID: 34596996 Free article. Norwegian.
[Investigation of anemia].
Schjesvold F, Wiencke K, Tjønnfjord GE. Schjesvold F, et al. Tidsskr Nor Laegeforen. 2013 Mar 19;133(6):610. doi: 10.4045/tidsskr.13.0256. Tidsskr Nor Laegeforen. 2013. PMID: 23552139 Free article. Norwegian. No abstract available.
Immunologiske mekanismer for drap av kreftceller.
Schjesvold FH. Schjesvold FH. Tidsskr Nor Laegeforen. 2017 Jan 10;137(1):58. doi: 10.4045/tidsskr.16.0963. eCollection 2017 Jan. Tidsskr Nor Laegeforen. 2017. PMID: 28073239 Free article. Norwegian. No abstract available.
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG). Hjorth M, et al. Eur J Haematol. 2012 Jun;88(6):485-96. doi: 10.1111/j.1600-0609.2012.01775.x. Epub 2012 Mar 30. Eur J Haematol. 2012. PMID: 22404182 Free PMC article. Clinical Trial.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Among authors: schjesvold f. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Among authors: schjesvold f. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
86 results